Amantadine and L-Carnitine treatment of chronic fatigue syndrome

Neuropsychobiology

Volumn 35, Issue 1, 1997, Pages 16-23

  Plioplys, Audrius V ^a,b   Plioplys, Sigita ^a  

^a MERCY HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Amantadine; Carnitine; Chronic Fatigue Syndrome; Fatigue

Indexed keywords

AMANTADINE; ANTILIPEMIC AGENT; CARNITINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ANOREXIA; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DRUG EFFICACY; ENERGY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LYMPHADENOPATHY; MALE; MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

AMANTADINE; ANTIVIRAL AGENTS; CARNITINE; CROSS-OVER STUDIES; FATIGUE SYNDROME, CHRONIC; HUMANS; NEUROLOGIC EXAMINATION; TREATMENT OUTCOME;

EID: 0031033813     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119325     Document Type: Article

References (35)

1. Lloyd AR, Hales JP, Gandevia SC: Muscle strcngh. endurance and recovery in the postinfection fatigue syndrome. J Neurol Neurosurg Psychiatry 1988:51:1316-1322.
2. Arnold DL, Bore PJ, Radda GK, et al: Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. Lancet 1984;i: 1367-1369.
3. Jamal GA, Hansen S: Post viral fatigue syndrome: Evidence for underlying organic disturbance in the muscle fiber. Eur Neurol 1989:29: 273-276.
4. Kent-Braun JA, Sharma KR. Weiner MW. et al: Central basis of muscle fatigue in chronic fatigue syndrome. Neurology 1993:43:125-131.
5. Riley MS, O’Brien CJ, McCluskey DR, et al: Aerobic work capacity in patients with chronic fatigue syndrome. BMJ 1990;301:953-956.
6. Edwards RHT, Newham DJ, PetersTJ: Muscle biochemistry and pathophysiology in postviral fatigue syndrome. Br Med Bull 1991:47:826-837.
7. 31P nuclear magnetic resonance spectroscopy. Chest 1992:102: 1716-1722.
8. Behan PO, Behan WMH: Postviral fatigue syndrome. CRC Crit Rev Neurobiol 1988:4:157-178
9. Behan WMH, Downie I, More IAR, et al: Changes in muscle mitochondria; In Dawson DM, Savin TD (eds): Chronic Fatigue Syndrome. Boston. Little, Brown. 1993, pp 131-140.
10. Behan WMH, Moore IAR, Behan PO: Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991:83:61.
11. Coulter DL: Carnitine, valproate and toxicity. J Child Neurol 1991;6:7-14.
12. Kuratsune H, Yamaguti K, Takahashi M, et al: Acylcamitine deficiency in Chronic Fatigue Syndrome. Clin infect Dis 1994:18(suppl 1): S62-67.
13. Plioplys AV, Plioplys S: Serum levels of carnitine in Chronic Fatigue Syndrome: Clinical correlates. Ncuropsychobiology 1995:32:132-138.
14. Plioplys AV, Bagherpour S, Kasnicka I: L-Carnitine as a treatment of lethargy in children with chronic neurologic handicaps. Br Dev 1994;16:146-149.
15. Plioplys AV, Kasnicka I: L-Carnitine as a treatment for Rettsyndrome. South Med J 1993:86: 1411-1413.
16. Chiba S, Ito M, Matsumoto H: Amantadine treatment for refractory pain in patients with multiple sclerosis. Can J Neurol Sei 1992:19: 309.
17. Murray TJ: Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sei 1985:12: 251-254.
18. Rosenberg GA, Appenzeller O: Amantadine, fatigue and multiple sclerosis. Can J Neurol Sei 1988:45:1104-1106.
19. Tennant FS, Sagherian AA: Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Int Med 1987:147:109-112.
20. Edwards RHT: Central versus peripheral mechanisms of fatigue in exercise. Muscle Nerve 1986:9:39-55.
21. The Canadian Multiple Sclerosis Research Group: A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sei 1987;14:273-278.
22. Wiggs JW: Letter to the editor. S D J Med 1991:30:279.
23. De Vivo DC, Tein I: Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990;5:134-141.
24. Plioplys S, Plioplys AV: Amantadine and L-carnitine therapy of Chronic Fatigue Syndrome: Preliminary results. Proc Am Assoc Chronic Fatigue Syndrome 1994:1:92.
25. Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:53-63.
26. Derogatis LR: SCL-R-90 Scoring Manual I: Scoring. Administration and Procedures. Baltimore. Johns Hopkins University School of Medicine Clinical Psychometrics Unit, 1977.
27. Wessely S, Powell R: Fatigue syndromes: a comparison of chronic ‘postviral’ fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psychiatry 1989:52:940-948.
28. Lloyd AR, Hickie I, Boughton CR, et al: Prevalence of chronic fatigue syndrome in an Australian population. Med J Aust 1990:153:522-528.
29. Sharpe MC, Archard LC, Banatvala JE, et al: A report - chronic fatigue syndrome: Guidelines for research. J R Soc Med 1991:84:118-121.
30. Holmes GP, Kaplan JE, Gantz NM, et al: Chronic fatigue syndrome: A working case definition. Ann Intern Med 1988;108:387-389.
31. Fukuda K, Strauss SE, Hickie I, et al: The Chronic Fatigue Syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-959.
32. Engle AG: Carnitine deficiency syndromes and lipid storage myopathies: in Engle AG. Banker. BQ (eds): Myology. New York. McGraw-Flill. 1986, pp 1663-1668.
33. Rebouche CJ, Engel AG: Carnitine metabolism and deficiency syndromes. Mayo Clin Proc 1983:58:533-540
34. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989: 46:1121-1123.
35. Kerlinger FN: Foundations of Behavioral Research. New York. Holt, Rinchard & Winston. 1973. p 548.